Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for del(5q) Myelodysplastic Syndrome
Articolo
Data di Pubblicazione:
2017
Citazione:
Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for del(5q) Myelodysplastic Syndrome / N.S. Fracchiolla, A. Iurlo, V. Ferla, B. Fattizzo, A. Freyrie, G. Reda, A. Cortelezzi. - In: CLINICAL LABORATORY. - ISSN 1433-6510. - 63:9(2017 Sep 01), pp. 1513-1517. [10.7754/Clin.Lab.2017.170322]
Abstract:
Background: Myelodysplastic syndromes with chromosome 5 long arm deletion (5q-MDS) may benefit from lenalidomide treatment. However, unresponsive patients have a high risk for clonal evolution and progression to acute myeloid leukemia. Case: We describe a 5q-patient treated with lenalidomide, who concomitantly developed acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm, a rare and highly aggressive lymphoma. Conclusions: Evolution of 5q-syndrome to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm may have occurred through various mechanisms, including persistence of neoplastic lenalidomide-resistant stem cells and selection of a more aggressive clone via lenalidomide augmentation of the ARPC1B gene, or because of lenalidomide stimulation on dendritic cells. Further studies are needed to clarify lenalidomide oncogenic potential.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
myelodysplastic syndromes; blastic plasmacytoid dendritic cell neoplasm; acute myeloid leukaemia; lenalidomide
Elenco autori:
N.S. Fracchiolla, A. Iurlo, V. Ferla, B. Fattizzo, A. Freyrie, G. Reda, A. Cortelezzi
Link alla scheda completa:
Link al Full Text: